drugset / Trial / NCT06863480
Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events
NaSingle-groupOpen-labelTreatment
Summary
In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.
Timeline
- Start
- 2026-03-02
- Primary completion
- 2028-07-30
- Completion
- 2028-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 6 mg/kg | Intravenous |